Eli Lilly and Company (NYSE: LLY) today announced positive results from the TRAILBLAZER-ALZ 6 Phase 3b study, showing a ...

The standard dosing regimen was 700 mg of donanemab for the first three infusions, then 1,400 mg for each infusion after that ...

Modified titration was associated with a 41% lower relative risk of ARIA-E than the standard dosing regimen. Topline results were announced from a phase 3b trial evaluating various dosing regimens of ...

Donanemab can slow the progression of Alzheimer’s disease. But what is the drug and how does it work? Here your questions on ...

Eli Lilly (LLY) announced “positive results” from the TRAILBLAZER-ALZ 6 Phase 3b study, showing a reduction in amyloid-related ...

Donanemab and another new drug for Alzheimer’s called Lecanemab have been billed as a huge step forward in research ...

There are four dementia-specific medications approved in Australia – donepezil, galantamine, rivastigmine, and memantine.

The Medicines and Healthcare products Regulatory Agency (MHRA) has today, 23 October 2024, approved a license for the ...

For the second time in recent months, a U.K. agency said the limited benefits of a new Alzheimer’s drug do not justify its ...

A new Alzheimer’s drug has been rejected by the health spending watchdog for general use within NHS England, with the ...

Donanemab marks a significant advancement in Alzheimer’s treatment, but NHS patients face a setback with NICE's rejection of ...